Comparing the current results to its competitors, Cormedix Inc reported Revenue increase in the 2 quarter 2026 by 156.52 % year on year. The sales growth was above Cormedix Inc 's competitors' average revenue growth of 13.82 %, achieved in the same quarter.
Cormedix Inc Net Income in the 2 quarter 2026 grew year on year by 226.41%, while most of its competitors have experienced a contraction in net income by -62.08 %.
Cormedix Inc 's Comment on Competition and Industry Peers
The company operates in a highly competitive drug and medical device industry characterized by rapid technological changes. Competitors include large and specialty pharmaceutical, biotechnology, and medical device companies, many of which possess greater financial, technical, and human resources, as well as more experience in drug and device development and commercialization. The company's product, DefenCath, is the only FDA-approved antimicrobial catheter lock solution in the United States. Currently, there are no known catheter lock solutions approved or under development by other companies in the U.S. for primary infection prevention. Some dialysis providers use anti-infective infused catheter caps or compounded antibiotic catheter lock solutions that are not FDA-approved. Key competitive factors in this market include established efficacy and safety, pricing and reimbursement mechanisms, clinical differentiation, and alignment with treatment guidelines.
March 26, 2025
In the fast-paced world of biopharmaceuticals, the stakes are high, and the scrutiny is relentless. Recently, CorMedix Inc. (NASDAQ: CRMD) found itself in the spotlight as Kirby McInerney LLP announced an investigation into the company over potential violations of federal securities laws. This investigation attracts attention not only for its legal implications but also for the broader context it reveals about CorMedix s business trajectory and its standing in the competitive landscape.The investigation centers on concerns that CorMedix and specific officers may have engaged in unlawful business practices. Such inquiries can often signal deeper issues within a company, potentially eroding investor confidence...
September 9, 2024
In a significant advancement for the field of biopharmaceuticals, CorMedix Inc. (Nasdaq: CRMD), a prominent player dedicated to the development of therapeutic solutions for severe and life-threatening health conditions, has announced a new multi-year commercial agreement. This agreement, hailed as a substantial milestone for the company, entails the supply of DefenCath, a novel formulation combining taurolidine and heparin, to a global healthcare partner s facilities in the United States.DefenCath is particularly notable for its potential benefits in preventing catheter-related infections, which pose a serious risk to patients with long-term indwelling catheters. By utilizing taurolidine, a compound known fo...
July 3, 2024
Introducing DefenCath: A Revolutionary Solution for Outpatient Dialysis and Inpatient UseCorMedix Inc., a prominent biopharmaceutical company, has recently made groundbreaking announcements regarding the availability of its flagship product, DefenCath. With the approval and reimbursement from the Center for Medicare and Medicaid Services (CMS), DefenCath is now commercially available for use in outpatient dialysis centers and vascular access clinics where patients receive outpatient dialysis and catheter placement services. Additionally, CorMedix has announced the commercial availability of DefenCath for U.S. inpatient use, further expanding the reach of this innovative catheter lock solution (CLS).As a comp...
June 6, 2024
BERKELEY HEIGHTS, N.J. June 6, 2024 In a substantial stride for healthcare innovation, biopharmaceutical company CorMedix Inc. (Nasdaq: CRMD) has announced major advancements for their flagship product, DefenCath. This progress includes a coveted pass-through status from the Center for Medicare and Medicaid Services (CMS), which bodes well for both the company’s prospects and the future of patient care. This status ensures separate reimbursement for DefenCath under the Out-Patient Prospective Payment System (OPPS) at least for two years and possibly extending up to three years. What This Means for Patients and Providers Pass-through status is a significant milestone in Medicare s reimbursement ecosyst...
April 15, 2024
CorMedix Inc., an industry-leading biopharmaceutical company committed to delivering innovative solutions for the treatment of life-threatening ailments, recently declared that their specialty product, DefenCath (Taurolidine and Heparin) catheter lock solution (CLS), has been launched as a commercial entity within the U.S. inpatient market.This breakthrough news was announced on April 15, 2024 and displays the ongoing effort of CorMedix Inc. to enhance and elevate the provisions of the healthcare ecosystem. As a company listed on Nasdaq (CRMD), CorMedix s announcement of this new chapter in the availability of therapeutic products reinforces the dramatic strides they are making within the biopharmaceutical ...
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Sources:
Cormedix Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cormedix Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
